P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)

ABSTRACT:

SUBMITTER: Usmani S 

PROVIDER: S-EPMC9430248 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature